http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 06 Oct 2026 07:35:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Knight+Therapeutics+Announces+Regulatory+Approval+of+NIKTIMVO%C2%AE+in+Brazil/27151915.html <p align="justify">MONTREAL, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (&quot;Knight&quot;) (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today it has received expedited regulatory approval under ANVISA’s rare disease pathway for NIKTIMVO® (axatilimab), for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients 6 years and older weighing at least 40 kg.1</p> <p align="justify">“For patients living with chronic graft-versus-host disease who have exhausted two prior lines of therapy, access to a new treatment option can be life-changing. NIKTIMVO® offers a first-in-class http://www.streetinsider.com/Press+Releases/Knight+Therapeutics+Announces+Regulatory+Approval+of+NIKTIMVO%C2%AE+in+Brazil/27151915.html Tue, 06 Oct 2026 07:35:00 -0400 GUD INCY http://www.streetinsider.com/Globe+Newswire/Knight+Therapeutics+Announces+Regulatory+Approval+of+NIKTIMVO%C2%AE+in+Brazil/27151915.html <p align="justify">MONTREAL, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (&quot;Knight&quot;) (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today it has received expedited regulatory approval under ANVISA’s rare disease pathway for NIKTIMVO® (axatilimab), for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients 6 years and older weighing at least 40 kg.1</p> <p align="justify">“For patients living with chronic graft-versus-host disease who have exhausted two prior lines of therapy, access to a new treatment option can be life-changing. NIKTIMVO® offers a first-in-class http://www.streetinsider.com/Globe+Newswire/Knight+Therapeutics+Announces+Regulatory+Approval+of+NIKTIMVO%C2%AE+in+Brazil/27151915.html Tue, 06 Oct 2026 07:35:00 -0400 GUD INCY http://www.streetinsider.com/Press+Releases/Knight+Therapeutics+Announces+Regulatory+Approval+of+NIKTIMVO%C2%AE+in+Brazil/27151915.html <p align="justify">MONTREAL, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (&quot;Knight&quot;) (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today it has received expedited regulatory approval under ANVISA’s rare disease pathway for NIKTIMVO® (axatilimab), for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients 6 years and older weighing at least 40 kg.1</p> <p align="justify">“For patients living with chronic graft-versus-host disease who have exhausted two prior lines of therapy, access to a new treatment option can be life-changing. NIKTIMVO® offers a first-in-class http://www.streetinsider.com/Press+Releases/Knight+Therapeutics+Announces+Regulatory+Approval+of+NIKTIMVO%C2%AE+in+Brazil/27151915.html Tue, 06 Oct 2026 07:35:00 -0400 GUD INCY http://www.streetinsider.com/Globe+Newswire/Knight+Therapeutics+Announces+Regulatory+Approval+of+NIKTIMVO%C2%AE+in+Brazil/27151915.html <p align="justify">MONTREAL, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (&quot;Knight&quot;) (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today it has received expedited regulatory approval under ANVISA’s rare disease pathway for NIKTIMVO® (axatilimab), for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients 6 years and older weighing at least 40 kg.1</p> <p align="justify">“For patients living with chronic graft-versus-host disease who have exhausted two prior lines of therapy, access to a new treatment option can be life-changing. NIKTIMVO® offers a first-in-class http://www.streetinsider.com/Globe+Newswire/Knight+Therapeutics+Announces+Regulatory+Approval+of+NIKTIMVO%C2%AE+in+Brazil/27151915.html Tue, 06 Oct 2026 07:35:00 -0400 GUD INCY http://www.streetinsider.com/Press+Releases/Knight+Therapeutics+Announces+Launch+of+TAVALISSE%C2%AE+in+Brazil/27151897.html <p align="justify">MONTREAL, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (&quot;Knight&quot;) (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today the launch of TAVALISSE® (fostamatinib disodium hexahydrate) in Brazil, for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.1</p> <p align="justify">“With today&apos;s launch, TAVALISSE® is now available to adults in Brazil living with chronic ITP who have not responded adequately to prior therapy. TAVALISSE® strengthens Knight’s hematology and oncology portfolio in Brazil alongside MINJUVI® and continues our track record of bringing innovative products to physicians http://www.streetinsider.com/Press+Releases/Knight+Therapeutics+Announces+Launch+of+TAVALISSE%C2%AE+in+Brazil/27151897.html Tue, 06 Oct 2026 07:30:00 -0400 GUD http://www.streetinsider.com/Globe+Newswire/Knight+Therapeutics+Announces+Launch+of+TAVALISSE%C2%AE+in+Brazil/27151897.html <p align="justify">MONTREAL, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (&quot;Knight&quot;) (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today the launch of TAVALISSE® (fostamatinib disodium hexahydrate) in Brazil, for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.1</p> <p align="justify">“With today&apos;s launch, TAVALISSE® is now available to adults in Brazil living with chronic ITP who have not responded adequately to prior therapy. TAVALISSE® strengthens Knight’s hematology and oncology portfolio in Brazil alongside MINJUVI® and continues our track record of bringing innovative products to physicians http://www.streetinsider.com/Globe+Newswire/Knight+Therapeutics+Announces+Launch+of+TAVALISSE%C2%AE+in+Brazil/27151897.html Tue, 06 Oct 2026 07:30:00 -0400 GUD http://www.streetinsider.com/Press+Releases/Kyowa+Kirin+and+Knight+Therapeutics+Enter+Into+Exclusive+Distribution+Agreement+for+POTELIGEO%C2%AE+%28mogamulizumab%29+for+Cutaneous+T-Cell+Lymphoma+%28CTCL%29+Patients+Across+Latin+America/27117587.html <ul class="bwlistdisc"> <li> <i>This agreement marks the first introduction of Kyowa Kirin's POTELIGEO® in Latin America and expands access for patients.</i> </li> <li> <i>Knight Therapeutics to exclusively distribute POTELIGEO® across Argentina, Brazil, Colombia and Mexico.</i> </li> <li> <i>The agreement supports Kyowa Kirin’s mission to address barriers to diagnosis, treatment access and disease awareness for CTCL patients across the region.</i> </li> </ul> <p> GALASHIELS &amp; MARLOW, U.K.--(BUSINESS WIRE)-- Kyowa Kirin International, a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), today announced the signing of an exclusive distribution agreement with Knight Therapeutics (“Knight”) (TSX: GUD) for the distribution of mogamulizumab in select countries in Latin America. </p><p> Under the http://www.streetinsider.com/Press+Releases/Kyowa+Kirin+and+Knight+Therapeutics+Enter+Into+Exclusive+Distribution+Agreement+for+POTELIGEO%C2%AE+%28mogamulizumab%29+for+Cutaneous+T-Cell+Lymphoma+%28CTCL%29+Patients+Across+Latin+America/27117587.html Tue, 29 Sep 2026 08:00:00 -0400 GUD KNBWY KYKOY http://www.streetinsider.com/Business+Wire/Kyowa+Kirin+and+Knight+Therapeutics+Enter+Into+Exclusive+Distribution+Agreement+for+POTELIGEO%C2%AE+%28mogamulizumab%29+for+Cutaneous+T-Cell+Lymphoma+%28CTCL%29+Patients+Across+Latin+America/27117587.html <ul class="bwlistdisc"> <li> <i>This agreement marks the first introduction of Kyowa Kirin's POTELIGEO® in Latin America and expands access for patients.</i> </li> <li> <i>Knight Therapeutics to exclusively distribute POTELIGEO® across Argentina, Brazil, Colombia and Mexico.</i> </li> <li> <i>The agreement supports Kyowa Kirin’s mission to address barriers to diagnosis, treatment access and disease awareness for CTCL patients across the region.</i> </li> </ul> <p> GALASHIELS &amp; MARLOW, U.K.--(BUSINESS WIRE)-- Kyowa Kirin International, a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), today announced the signing of an exclusive distribution agreement with Knight Therapeutics (“Knight”) (TSX: GUD) for the distribution of mogamulizumab in select countries in Latin America. </p><p> Under the http://www.streetinsider.com/Business+Wire/Kyowa+Kirin+and+Knight+Therapeutics+Enter+Into+Exclusive+Distribution+Agreement+for+POTELIGEO%C2%AE+%28mogamulizumab%29+for+Cutaneous+T-Cell+Lymphoma+%28CTCL%29+Patients+Across+Latin+America/27117587.html Tue, 29 Sep 2026 08:00:00 -0400 GUD KNBWY KYKOY http://www.streetinsider.com/Press+Releases/Kyowa+Kirin+and+Knight+Therapeutics+Enter+Into+Exclusive+Distribution+Agreement+for+POTELIGEO%C2%AE+%28mogamulizumab%29+for+Cutaneous+T-Cell+Lymphoma+%28CTCL%29+Patients+Across+Latin+America/27117587.html <ul class="bwlistdisc"> <li> <i>This agreement marks the first introduction of Kyowa Kirin's POTELIGEO® in Latin America and expands access for patients.</i> </li> <li> <i>Knight Therapeutics to exclusively distribute POTELIGEO® across Argentina, Brazil, Colombia and Mexico.</i> </li> <li> <i>The agreement supports Kyowa Kirin’s mission to address barriers to diagnosis, treatment access and disease awareness for CTCL patients across the region.</i> </li> </ul> <p> GALASHIELS &amp; MARLOW, U.K.--(BUSINESS WIRE)-- Kyowa Kirin International, a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), today announced the signing of an exclusive distribution agreement with Knight Therapeutics (“Knight”) (TSX: GUD) for the distribution of mogamulizumab in select countries in Latin America. </p><p> Under the http://www.streetinsider.com/Press+Releases/Kyowa+Kirin+and+Knight+Therapeutics+Enter+Into+Exclusive+Distribution+Agreement+for+POTELIGEO%C2%AE+%28mogamulizumab%29+for+Cutaneous+T-Cell+Lymphoma+%28CTCL%29+Patients+Across+Latin+America/27117587.html Tue, 29 Sep 2026 08:00:00 -0400 GUD KNBWY KYKOY http://www.streetinsider.com/Business+Wire/Kyowa+Kirin+and+Knight+Therapeutics+Enter+Into+Exclusive+Distribution+Agreement+for+POTELIGEO%C2%AE+%28mogamulizumab%29+for+Cutaneous+T-Cell+Lymphoma+%28CTCL%29+Patients+Across+Latin+America/27117587.html <ul class="bwlistdisc"> <li> <i>This agreement marks the first introduction of Kyowa Kirin's POTELIGEO® in Latin America and expands access for patients.</i> </li> <li> <i>Knight Therapeutics to exclusively distribute POTELIGEO® across Argentina, Brazil, Colombia and Mexico.</i> </li> <li> <i>The agreement supports Kyowa Kirin’s mission to address barriers to diagnosis, treatment access and disease awareness for CTCL patients across the region.</i> </li> </ul> <p> GALASHIELS &amp; MARLOW, U.K.--(BUSINESS WIRE)-- Kyowa Kirin International, a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), today announced the signing of an exclusive distribution agreement with Knight Therapeutics (“Knight”) (TSX: GUD) for the distribution of mogamulizumab in select countries in Latin America. </p><p> Under the http://www.streetinsider.com/Business+Wire/Kyowa+Kirin+and+Knight+Therapeutics+Enter+Into+Exclusive+Distribution+Agreement+for+POTELIGEO%C2%AE+%28mogamulizumab%29+for+Cutaneous+T-Cell+Lymphoma+%28CTCL%29+Patients+Across+Latin+America/27117587.html Tue, 29 Sep 2026 08:00:00 -0400 GUD KNBWY KYKOY http://www.streetinsider.com/Press+Releases/Kyowa+Kirin+and+Knight+Therapeutics+Enter+Into+Exclusive+Distribution+Agreement+for+POTELIGEO%C2%AE+%28mogamulizumab%29+for+Cutaneous+T-Cell+Lymphoma+%28CTCL%29+Patients+Across+Latin+America/27117587.html <ul class="bwlistdisc"> <li> <i>This agreement marks the first introduction of Kyowa Kirin's POTELIGEO® in Latin America and expands access for patients.</i> </li> <li> <i>Knight Therapeutics to exclusively distribute POTELIGEO® across Argentina, Brazil, Colombia and Mexico.</i> </li> <li> <i>The agreement supports Kyowa Kirin’s mission to address barriers to diagnosis, treatment access and disease awareness for CTCL patients across the region.</i> </li> </ul> <p> GALASHIELS &amp; MARLOW, U.K.--(BUSINESS WIRE)-- Kyowa Kirin International, a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), today announced the signing of an exclusive distribution agreement with Knight Therapeutics (“Knight”) (TSX: GUD) for the distribution of mogamulizumab in select countries in Latin America. </p><p> Under the http://www.streetinsider.com/Press+Releases/Kyowa+Kirin+and+Knight+Therapeutics+Enter+Into+Exclusive+Distribution+Agreement+for+POTELIGEO%C2%AE+%28mogamulizumab%29+for+Cutaneous+T-Cell+Lymphoma+%28CTCL%29+Patients+Across+Latin+America/27117587.html Tue, 29 Sep 2026 08:00:00 -0400 GUD KNBWY KYKOY http://www.streetinsider.com/Business+Wire/Kyowa+Kirin+and+Knight+Therapeutics+Enter+Into+Exclusive+Distribution+Agreement+for+POTELIGEO%C2%AE+%28mogamulizumab%29+for+Cutaneous+T-Cell+Lymphoma+%28CTCL%29+Patients+Across+Latin+America/27117587.html <ul class="bwlistdisc"> <li> <i>This agreement marks the first introduction of Kyowa Kirin's POTELIGEO® in Latin America and expands access for patients.</i> </li> <li> <i>Knight Therapeutics to exclusively distribute POTELIGEO® across Argentina, Brazil, Colombia and Mexico.</i> </li> <li> <i>The agreement supports Kyowa Kirin’s mission to address barriers to diagnosis, treatment access and disease awareness for CTCL patients across the region.</i> </li> </ul> <p> GALASHIELS &amp; MARLOW, U.K.--(BUSINESS WIRE)-- Kyowa Kirin International, a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), today announced the signing of an exclusive distribution agreement with Knight Therapeutics (“Knight”) (TSX: GUD) for the distribution of mogamulizumab in select countries in Latin America. </p><p> Under the http://www.streetinsider.com/Business+Wire/Kyowa+Kirin+and+Knight+Therapeutics+Enter+Into+Exclusive+Distribution+Agreement+for+POTELIGEO%C2%AE+%28mogamulizumab%29+for+Cutaneous+T-Cell+Lymphoma+%28CTCL%29+Patients+Across+Latin+America/27117587.html Tue, 29 Sep 2026 08:00:00 -0400 GUD KNBWY KYKOY http://www.streetinsider.com/Press+Releases/Knight+Therapeutics+Enters+into+Exclusive+Distribution+Agreement+with+Kyowa+Kirin+International+for+Poteligeo%C2%AE+%28Mogamulizumab%29/27117414.html <p align="justify">MONTREAL, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (&quot;Knight&quot;) (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today the signing of an exclusive distribution agreement with Kyowa Kirin International (“KKI”), a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151) (“Kyowa Kirin”), a Japan-based global specialty pharmaceutical company, for mogamulizumab (sold as POTELIGEO® in the United States and Europe) across certain Latin American countries. Under the terms of this agreement Knight will be responsible for obtaining regulatory approval and commercializing mogamulizumab in Brazil, Mexico, Colombia and Argentina.</p> <p align="justify">Mogamulizumab is a humanized monoclonal antibody http://www.streetinsider.com/Press+Releases/Knight+Therapeutics+Enters+into+Exclusive+Distribution+Agreement+with+Kyowa+Kirin+International+for+Poteligeo%C2%AE+%28Mogamulizumab%29/27117414.html Tue, 29 Sep 2026 07:30:00 -0400 GUD http://www.streetinsider.com/Globe+Newswire/Knight+Therapeutics+Enters+into+Exclusive+Distribution+Agreement+with+Kyowa+Kirin+International+for+Poteligeo%C2%AE+%28Mogamulizumab%29/27117414.html <p align="justify">MONTREAL, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (&quot;Knight&quot;) (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today the signing of an exclusive distribution agreement with Kyowa Kirin International (“KKI”), a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151) (“Kyowa Kirin”), a Japan-based global specialty pharmaceutical company, for mogamulizumab (sold as POTELIGEO® in the United States and Europe) across certain Latin American countries. Under the terms of this agreement Knight will be responsible for obtaining regulatory approval and commercializing mogamulizumab in Brazil, Mexico, Colombia and Argentina.</p> <p align="justify">Mogamulizumab is a humanized monoclonal antibody http://www.streetinsider.com/Globe+Newswire/Knight+Therapeutics+Enters+into+Exclusive+Distribution+Agreement+with+Kyowa+Kirin+International+for+Poteligeo%C2%AE+%28Mogamulizumab%29/27117414.html Tue, 29 Sep 2026 07:30:00 -0400 GUD http://www.streetinsider.com/Press+Releases/Knight+Therapeutics+Inc.+places+No.+345+on+The+Globe+and+Mail%E2%80%99s+eighth+annual+ranking+of+Canada%26apos%3Bs+Top+Growing+Companies/27104759.html <p align="justify">MONTREAL, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) (“Knight” or “the Company”) is pleased to announce it has ranked No. 345 on the 2026 Report on Business magazine’s ranking of Canada’s Top Growing Companies.</p> <p align="justify">Canada’s Top Growing Companies ranks Canadian companies on three-year revenue growth. Knight earned its spot with three-year growth of 53%.</p> <p align="justify">“We’re honored to be recognized as one of Canada’s Top Growing Companies by <em>Report on Business </em>for the sixth consecutive year,” said Samira Sakhia, President and CEO of Knight. “This recognition belongs to our team across http://www.streetinsider.com/Press+Releases/Knight+Therapeutics+Inc.+places+No.+345+on+The+Globe+and+Mail%E2%80%99s+eighth+annual+ranking+of+Canada%26apos%3Bs+Top+Growing+Companies/27104759.html Fri, 25 Sep 2026 09:55:00 -0400 GUD http://www.streetinsider.com/Globe+Newswire/Knight+Therapeutics+Inc.+places+No.+345+on+The+Globe+and+Mail%E2%80%99s+eighth+annual+ranking+of+Canada%26apos%3Bs+Top+Growing+Companies/27104759.html <p align="justify">MONTREAL, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) (“Knight” or “the Company”) is pleased to announce it has ranked No. 345 on the 2026 Report on Business magazine’s ranking of Canada’s Top Growing Companies.</p> <p align="justify">Canada’s Top Growing Companies ranks Canadian companies on three-year revenue growth. Knight earned its spot with three-year growth of 53%.</p> <p align="justify">“We’re honored to be recognized as one of Canada’s Top Growing Companies by <em>Report on Business </em>for the sixth consecutive year,” said Samira Sakhia, President and CEO of Knight. “This recognition belongs to our team across http://www.streetinsider.com/Globe+Newswire/Knight+Therapeutics+Inc.+places+No.+345+on+The+Globe+and+Mail%E2%80%99s+eighth+annual+ranking+of+Canada%26apos%3Bs+Top+Growing+Companies/27104759.html Fri, 25 Sep 2026 09:55:00 -0400 GUD http://www.streetinsider.com/Press+Releases/Knight+Therapeutics+Announces+Regulatory+Submission+of+GEMTESA%C2%AE+in+Canada/27061127.html <p align="justify">MONTREAL, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (&quot;Knight&quot;) (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today that Knight’s New Drug Submission (NDS) for GEMTESA® (vibegron), proposed for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults, and OAB with symptoms of urge urinary incontinence, urgency, urinary frequency, and nocturia in adult males on pharmacological therapy for benign prostatic hyperplasia (BPH), has been accepted for review by Health Canada.</p> <p align="justify">&quot;For patients living with overactive bladder, and for adult males managing OAB alongside BPH, http://www.streetinsider.com/Press+Releases/Knight+Therapeutics+Announces+Regulatory+Submission+of+GEMTESA%C2%AE+in+Canada/27061127.html Tue, 15 Sep 2026 07:30:00 -0400 GUD http://www.streetinsider.com/Globe+Newswire/Knight+Therapeutics+Announces+Regulatory+Submission+of+GEMTESA%C2%AE+in+Canada/27061127.html <p align="justify">MONTREAL, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (&quot;Knight&quot;) (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today that Knight’s New Drug Submission (NDS) for GEMTESA® (vibegron), proposed for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults, and OAB with symptoms of urge urinary incontinence, urgency, urinary frequency, and nocturia in adult males on pharmacological therapy for benign prostatic hyperplasia (BPH), has been accepted for review by Health Canada.</p> <p align="justify">&quot;For patients living with overactive bladder, and for adult males managing OAB alongside BPH, http://www.streetinsider.com/Globe+Newswire/Knight+Therapeutics+Announces+Regulatory+Submission+of+GEMTESA%C2%AE+in+Canada/27061127.html Tue, 15 Sep 2026 07:30:00 -0400 GUD http://www.streetinsider.com/Press+Releases/Knight+Therapeutics+Announces+Regulatory+Approval+of+TAVALISSE%C2%AE+in+Colombia/27014059.html <p align="justify">MONTREAL, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (&quot;Knight&quot;) (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today that it has received regulatory approval from INVIMA, the Colombian health regulatory agency, for TAVALISSE® (fostamatinib disodium hexahydrate) for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response, loss of response, or intolerance to prior treatment with corticosteroids and intravenous immunoglobulin.1</p> <p align="justify">“We are pleased to receive regulatory approval of TAVALISSE in Colombia, providing an important new therapeutic option http://www.streetinsider.com/Press+Releases/Knight+Therapeutics+Announces+Regulatory+Approval+of+TAVALISSE%C2%AE+in+Colombia/27014059.html Tue, 01 Sep 2026 18:00:00 -0400 GUD http://www.streetinsider.com/Globe+Newswire/Knight+Therapeutics+Announces+Regulatory+Approval+of+TAVALISSE%C2%AE+in+Colombia/27014059.html <p align="justify">MONTREAL, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (&quot;Knight&quot;) (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today that it has received regulatory approval from INVIMA, the Colombian health regulatory agency, for TAVALISSE® (fostamatinib disodium hexahydrate) for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response, loss of response, or intolerance to prior treatment with corticosteroids and intravenous immunoglobulin.1</p> <p align="justify">“We are pleased to receive regulatory approval of TAVALISSE in Colombia, providing an important new therapeutic option http://www.streetinsider.com/Globe+Newswire/Knight+Therapeutics+Announces+Regulatory+Approval+of+TAVALISSE%C2%AE+in+Colombia/27014059.html Tue, 01 Sep 2026 18:00:00 -0400 GUD http://www.streetinsider.com/Press+Releases/Knight+Therapeutics+Announces+Supplemental+Regulatory+Submission+for+MINJUVI%C2%AE+%28tafasitamab%29+in+Brazil/26991515.html <p align="justify">MONTREAL, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (&quot;Knight&quot;) (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today that it has submitted a supplemental application to ANVISA, the Brazilian health regulatory agency, seeking approval for an additional indication for MINJUVI® (tafasitamab) in combination with lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). The supplemental application for the additional indication was selected for review under Project Orbis.</p> <p align="justify">“This supplemental submission to ANVISA http://www.streetinsider.com/Press+Releases/Knight+Therapeutics+Announces+Supplemental+Regulatory+Submission+for+MINJUVI%C2%AE+%28tafasitamab%29+in+Brazil/26991515.html Thu, 27 Aug 2026 18:00:00 -0400 A.08439236 A.17568957 GUD INCY O.00059377 O.00160346 O.04889877 O.17511696 http://www.streetinsider.com/Globe+Newswire/Knight+Therapeutics+Announces+Supplemental+Regulatory+Submission+for+MINJUVI%C2%AE+%28tafasitamab%29+in+Brazil/26991515.html <p align="justify">MONTREAL, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (&quot;Knight&quot;) (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today that it has submitted a supplemental application to ANVISA, the Brazilian health regulatory agency, seeking approval for an additional indication for MINJUVI® (tafasitamab) in combination with lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). The supplemental application for the additional indication was selected for review under Project Orbis.</p> <p align="justify">“This supplemental submission to ANVISA http://www.streetinsider.com/Globe+Newswire/Knight+Therapeutics+Announces+Supplemental+Regulatory+Submission+for+MINJUVI%C2%AE+%28tafasitamab%29+in+Brazil/26991515.html Thu, 27 Aug 2026 18:00:00 -0400 A.08439236 A.17568957 GUD INCY O.00059377 O.00160346 O.04889877 O.17511696 http://www.streetinsider.com/Press+Releases/Knight+Therapeutics+Announces+Supplemental+Regulatory+Submission+for+MINJUVI%C2%AE+%28tafasitamab%29+in+Brazil/26991515.html <p align="justify">MONTREAL, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (&quot;Knight&quot;) (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today that it has submitted a supplemental application to ANVISA, the Brazilian health regulatory agency, seeking approval for an additional indication for MINJUVI® (tafasitamab) in combination with lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). The supplemental application for the additional indication was selected for review under Project Orbis.</p> <p align="justify">“This supplemental submission to ANVISA http://www.streetinsider.com/Press+Releases/Knight+Therapeutics+Announces+Supplemental+Regulatory+Submission+for+MINJUVI%C2%AE+%28tafasitamab%29+in+Brazil/26991515.html Thu, 27 Aug 2026 18:00:00 -0400 A.08439236 A.17568957 GUD INCY O.00059377 O.00160346 O.04889877 O.17511696 http://www.streetinsider.com/Globe+Newswire/Knight+Therapeutics+Announces+Supplemental+Regulatory+Submission+for+MINJUVI%C2%AE+%28tafasitamab%29+in+Brazil/26991515.html <p align="justify">MONTREAL, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (&quot;Knight&quot;) (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today that it has submitted a supplemental application to ANVISA, the Brazilian health regulatory agency, seeking approval for an additional indication for MINJUVI® (tafasitamab) in combination with lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). The supplemental application for the additional indication was selected for review under Project Orbis.</p> <p align="justify">“This supplemental submission to ANVISA http://www.streetinsider.com/Globe+Newswire/Knight+Therapeutics+Announces+Supplemental+Regulatory+Submission+for+MINJUVI%C2%AE+%28tafasitamab%29+in+Brazil/26991515.html Thu, 27 Aug 2026 18:00:00 -0400 A.08439236 A.17568957 GUD INCY O.00059377 O.00160346 O.04889877 O.17511696 http://www.streetinsider.com/Press+Releases/Knight+Therapeutics+Announces+Supplemental+Regulatory+Submission+for+MINJUVI%C2%AE+%28tafasitamab%29+in+Brazil/26991515.html <p align="justify">MONTREAL, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (&quot;Knight&quot;) (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today that it has submitted a supplemental application to ANVISA, the Brazilian health regulatory agency, seeking approval for an additional indication for MINJUVI® (tafasitamab) in combination with lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). The supplemental application for the additional indication was selected for review under Project Orbis.</p> <p align="justify">“This supplemental submission to ANVISA http://www.streetinsider.com/Press+Releases/Knight+Therapeutics+Announces+Supplemental+Regulatory+Submission+for+MINJUVI%C2%AE+%28tafasitamab%29+in+Brazil/26991515.html Thu, 27 Aug 2026 18:00:00 -0400 A.08439236 A.17568957 GUD INCY O.00059377 O.00160346 O.04889877 O.17511696